Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise
beta
Latest Financials
Filings:
By Category
By Date
Search Filings
Institutional Holders
beta
Earnings Transcripts
beta
Global Search
Company Exhibits:
Indentures
Material Contracts & Credit Agreements
Plans of Reorganization
Articles and Bylaws
Underwriting Agreements
SEC Edgar
LENSAR, Inc.
SIC 3841 · Surgical & Medical Instruments & Apparatus
Notes
Support
about
terms
Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise.com
Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise.com
beta
Latest Financials
Filings:
Category
Date
Search Filings
Institutional Holders
beta
Earnings Transcripts
beta
Global Search
SEC Edgar
LENSAR, Inc.
SIC 3841 · Surgical & Medical Instruments & Apparatus
Notes
Support
about
terms
Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise.com
beta
Latest Financials
Filings:
Category
Date
Search Filings
Institutional Holders
beta
Earnings Transcripts
beta
Global Search
SEC Edgar
LENSAR, Inc.
SIC 3841 · Surgical & Medical Instruments & Apparatus
Notes
Support
about
terms
$
LNSR
LENSAR, Inc.
CIK:
0001320350
|
SEC Filings
Income Statement
Cash Flow
Balance Sheet
v3.26.1
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Revenue
Product and service revenue
$ 14,723
$ 12,290
$ 26,470
$ 24,565
Lease
1,772
1,645
3,453
3,529
Total revenue
16,495
13,935
29,923
28,094
Cost of revenue (exclusive of amortization)
Total cost of revenue
6,719
6,911
13,765
13,945
Operating expenses
Selling, general and administrative expenses
6,141
11,658
8,670
22,807
Research and development expenses
1,273
1,425
2,658
2,959
Amortization of intangible assets
228
230
457
462
Total operating expenses
7,642
13,313
11,785
26,228
Operating income (loss)
2,134
(6,289)
4,373
(12,079)
Other income (expense)
Change in fair value of warrant liabilities
1,230
4,332
25,178
(17,382)
Acquisition-related income
0
0
10,000
0
Other income, net
171
193
316
352
Net income (loss)
3,535
(1,764)
39,867
(29,109)
Other comprehensive income (loss)
Change in unrealized loss on investments
0
(6)
(4)
(9)
Net income (loss) and comprehensive income (loss)
$ 3,535
$ (1,770)
$ 39,863
$ (29,118)
Income (loss) per common share:
Basic
$ 0.14
$ (0.15)
$ 1.62
$ (2.46)
Diluted
$ 0.1
$ (0.15)
$ 0.61
$ (2.46)
Weighted-average number of common shares used in calculation of net income (loss) per common share:
Basic
12,297
11,937
12,230
11,856
Diluted
23,027
11,937
24,024
11,856
Product
Revenue
Product and service revenue
$ 13,042
$ 10,910
$ 23,118
$ 21,828
Cost of revenue (exclusive of amortization)
Total cost of revenue
3,839
4,315
7,786
8,781
Lease
Revenue
Lease
1,772
1,645
3,453
3,529
Cost of revenue (exclusive of amortization)
Total cost of revenue
851
859
1,740
1,689
Service
Revenue
Product and service revenue
1,681
1,380
3,352
2,737
Cost of revenue (exclusive of amortization)
Total cost of revenue
$ 2,029
$ 1,737
$ 4,239
$ 3,475
v3.26.1
CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Cash flows from operating activities
Net income (loss)
$ 39,867
$ (29,109)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation
1,782
1,709
Amortization of intangible assets
457
462
Non-cash operating lease cost
371
276
Provision for expected credit losses
18
(64)
Write-down of inventory
36
Loss on disposal of property and equipment
58
Stock-based compensation expense
1,037
1,420
Change in fair value of warrant liabilities
(25,178)
17,382
Acquisition-related income
(10,000)
0
Amortization on investments, net
1
(98)
Changes in operating assets and liabilities:
Accounts receivable
190
1,193
Notes receivable
(58)
333
Prepaid and other current assets
(1,317)
625
Inventories
(4,006)
(10,763)
Accounts payable
(4,040)
5,319
Accrued liabilities
(3,043)
(1,081)
Deferred revenue
(185)
692
Operating lease liabilities
(353)
(283)
Other
23
(7)
Net cash used in operating activities
(4,398)
(11,936)
Cash flows from investing activities
Investment maturities
5,000
5,000
Purchase of investments
(11,878)
Purchase of property and equipment
(35)
(83)
Net cash provided by (used in) investing activities
4,965
(6,961)
Cash flows from financing activities
Proceeds from issuance of common stock through option exercises
55
34
Proceeds from issuance of common stock under employee stock purchase plan
259
175
Net settlement of stock-based compensation awards
(290)
(425)
Proceeds from acquisition-related deposit
10,000
Net cash provided by financing activities
24
9,784
Net increase (decrease) in cash and cash equivalents
591
(9,113)
Cash and cash equivalents at beginning of the period
12,974
16,263
Cash and cash equivalents at end of the period
13,565
7,150
Supplemental schedule of non-cash investing and financing activities
Transfer from Inventories to Equipment under lease, net
$ 617
$ 3,538
v3.26.1
CONDENSED BALANCE SHEETS (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2026
Dec. 31, 2025
Current assets:
Cash and cash equivalents
$ 13,565
$ 12,974
Short-term investments
0
5,004
Accounts receivable, net of allowance of $79 and $62, respectively
6,170
6,377
Notes receivable, net of allowance of $10 and $6, respectively
501
295
Inventories
24,871
21,520
Prepaid and other current assets
1,919
601
Total current assets
47,026
46,771
Property and equipment, net
445
505
Equipment under lease, net
14,414
15,485
Notes and other receivables, long-term, net of allowance of $12 and $15, respectively
582
731
Intangible assets, net
4,734
5,191
Other assets
2,357
2,747
Total assets
69,558
71,430
Current liabilities:
Accounts payable
11,193
18,982
Accrued liabilities
4,728
7,771
Deferred revenue
2,927
3,074
Operating lease liabilities
792
747
Acquisition-related deposit
10,000
Total current liabilities
19,640
40,574
Long-term accounts payable
3,750
Long-term operating lease liabilities
1,589
1,988
Warrant liabilities
15,016
40,194
Other long-term liabilities
874
909
Total liabilities
40,869
83,665
Commitments and contingencies (Note 10)
Series A Redeemable Convertible Preferred Stock, par value $0.01 per share, 20 shares authorized at June 30, 2026 and December 31, 2025; 20 shares issued and outstanding at June 30, 2026 and December 31, 2025; aggregate liquidation preference of $20,000 at June 30, 2026 and December 31, 2025
13,784
13,784
Stockholders' equity (deficit):
Preferred stock, par value $0.01 per share, 9,980 shares authorized at June 30, 2026 and December 31, 2025; no shares issued and outstanding at June 30, 2026 and December 31, 2025
Common stock, par value $0.01 per share, 150,000 shares authorized at June 30, 2026 and December 31, 2025; 12,282 and 11,993 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively
123
120
Additional paid-in capital
152,490
151,432
Accumulated other comprehensive income
0
4
Accumulated deficit
(137,708)
(177,575)
Total stockholders' equity (deficit)
14,905
(26,019)
Total liabilities, redeemable convertible preferred stock, and stockholders' (deficit) equity
$ 69,558
$ 71,430